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Background: Helicobacter pylori (H. pylori) infection is known as a major etiologic factor for a variety of gastroduodenal diseases. 
In Iran, with a high rate of H. pylori infection close to 90%, numerous studies have revealed many aspects of interaction between the 
bacterium, mucosal surface and induction of disease outcome. The organism is genetically diverse and several virulence factors are 
attributed to the more virulent strains. The well-characterized virulence factors of H. pylori are cytotoxin associated gene A and 
vacuolating cytotoxin gene A. The distribution pattern of H. pylori genotypes and its association with disease status varies 
geographically. The present review focused on the virulence factors and genotyping of H. pylori in relation to gastroduodenal 
disorders in different regions of Iran. Methods: In total, 398 studies were reported on different aspects related to H. pylori in our 
electronic search from 1995-2011. H. pylori infection and its virulence factors in association with disease status were investigated in 
159 reports. Looking specifically at the gastrointestinal tract disorders, the most relevant reports including 37 papers were selected. 
Results: We found no correlation of cagA genotype and disease status in the majority of studies, whereas vacA was demonstrated as 
a useful marker in predicting the disease outcome. The results of reports on other virulence factors of H. pylori such as blood group 
antigen-binding adhesion gene A, the induced by contact with epithelium gene A, the outer inflammatory protein A, the duodenal 
ulcer promoting gene A, and Helicobacter outer membrane gene and their relation with disease status were contradictory. 
Conclusions: Although different markers of H. pylori were emphasized as useful when predicting disease outcomes in some studies, 
the inconsistent researches and the scarcity of data made any conclusion or even comparison impossible. Considering the gap of 
information observed during our search relating to genotyping and other aspects of H. pylori infection, further investigations are 
suggested. 
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INTRODUCTION 
 
Helicobacter pylori (H. pylori) - gram-negative, spiral-
shaped, microaerophilic bacterium is one of the 
most prevalent bacterial infections throughout the 
world affecting half of the world population.[1] The 
distribution pattern of H. pylori infection ranges 
from 25-50% in developed countries to more than 
80% in the developing world.[2] Low socioeconomic 
status and education level, crowded living places in 
childhood, and poor oral hygiene are among risk 
factors for carrying H. pylori.[3-5] It has been 
implicated as a major player in several 
gastrointestinal diseases as well as a number of 
extra gastric related disorders.[6-8] 
H. pylori is genetically diverse and several virulence 
factors have been attributed to the more virulent 
strains. The presence of flagella, which allows the 
bacterium to move and find a more livable 
environment within the stomach, and the ability to 
 
produce ammonia from urea using its urease 
enzyme are two certain capabilities of H. pylori to 
survive the harsh environment of the stomach.7 The 
most studied virulence markers of H. pylori include 
a cytotoxin-associated gene pathogenicity-island 
(cag PAI), a vacuolating cytotoxin gene A (vacA), 
and a blood group of antigen-binding adhesion 
gene A (babA).  
 
In Iran, H. pylori infection is present in nearly 90% 
of adult population[9] and appears to occur early in 
life, with > 50% of children infected before age 15.[10] 
Besides the fact that H. pylori was introduced as a 
class I carcinogen,[11] the infection is difficult to cure 
and requires various combination therapies.[12] On 
the other hand, a high rate of antibiotic resistance 
for various antimicrobials is considered as the 
major cause of the H. pylori treatment failure.[13] The 
low eradication rate[14] and a considerable 
reinfection rate (20%)[15] indicate the significance of 
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controlling H. pylori infection as an important health 
problem in Iran. Diagnostic methods, pathogenesis of 
H. pylori towards various diseases, treatment strategies 
and evaluation of bacterial resistance against some 
antimicrobials leading to treatment failure, have been 
all the matters of interest for numerous studies 
performed in Iran. The present review however, has 
focused on virulence factors and genotyping of H. 
pylori in relation to gastroduodenal disorders for which 
we found no comprehensive review in Iranian 
literatures. 
 
Methods 
 
To conduct a systematic review, the primary search 
was performed and the terms "Helicobacter pylori" as 
title and "Iran" as address were looked up within the 
time-span of 1995-2011. We performed our search 
using the Web of Knowledge database where the most 
relevant studies in the fields of microbiology and 
gastroenterology were indexed as ISI (Institute for 
Scientific Information). In total, 398 studies were 
reported on different aspects related to H. pylori in our 
electronic search. Based on title screening, we 
categorized all the papers into six major categories 
including virulence factors, treatment and therapy 
strategies, antimicrobial resistances, disease 
associations, and diagnostic methods. The other 
aspects such as immunological, biotechnological, and 
pharmacological researches were categorized as 
"others". H. pylori infection and its virulence factors in 
association with disease status were investigated in 159 
reports. Looking specifically at the gastrointestinal 
tract disorders, the most relevant reports including 37 
papers were selected. Other publications related to H. 
pylori infection and extra digestive disorders such as 
Down syndrome, metabolic syndrome, and anemia 
were excluded. We included the relevant original and 
review articles and abstracts indexed as ISI and all the 
selected papers were fully reviewed. Hand searching, 
we also included the references of the selected articles 
indexed as ISI or found in Google Scholar database as 
well as those published in national Iranian journals (in 
English) and not indexed as ISI since 1995. In our 
study, H. pylori infection and gastrointestinal tract 
pathogenesis along with genotyping and disease 
association were discussed as two main sections in 
details. 
 
H. pylori infection and gastrointestinal tract 
pathogenesis 
Chronic gastritis and peptic ulcer disease (PUD) 
H. pylori colonization is known as the main cause of 
gastritis and PUD.[9,16] The frequencies of gastritis and 
PUD among Iranian patients with H. pylori infection 
are reported to range from 25-79% and 11-62%, 
respectively. In a study by Sotoudeh et al.,[17] 508 
participants were enrolled in a national population-
based endoscopic survey. Mucosal biopsies were 
obtained from different sites of the gastrointestinal 
tract. The number of polymorphic nuclear leukocytes 
(PMN) and mononuclear (MN) cells for chronic 
gastritis were assessed. Both PMN and MN 
infiltrations correlated strongly with H. pylori infection 
being maximum for the antrum (odds ratio (OR) = 9.4) 
and the minimum for the gastric body (OR = 1.7).[17] 
Atrophy, intestinal metaplasia (IM), and dysplasia 
Chronic gastritis causes repeated and ongoing injury 
and destruction of the epithelial cells. In some patients 
this progresses to mucosal atrophy, IM and dysplasia, 
eventually ending in gastric cancer (GC).[17] The 
histopathological findings in particular atrophy and IM 
indicated no correlation with H. pylori virulence factors 
in the first-degree relatives of GC patients.[18] However, 
an increasing risk of GC was revealed due to the 
correlation between histological findings, as pre-
neoplastic changes, and virulence factors of 207 H. 
pylori infected patients in another study.[19] 
Gastric cancer (GC) 
H. pylori infection to be a cause of GC was firstly 
suggested by Warren.[20] GC is the fourth most common 
malignancy in the world and H. pylori infection has 
been attributed to over 63% of all cases of GC 
worldwide.[21] In Iran, the high rate of H. pylori 
infection, ranging from 42- 89%, has been reported for 
the areas with higher incidence of GC (the northern 
and northwestern regions).[22] In Ardabil, northwest of 
Iran, a province with high incidence of GC,[23] the 
prevalence of H. pylori infection has been estimated as 
82.2% in the study population. Chronic gastritis was 
also noticed in more than 90% of subjects. Moreover, 
atrophy, IM, and dysplasia were seen in 71.8% of 
subjects indicating the significant correlation of gastric 
precancerous lesions with H. pylori infection in this 
study.[22] A significant correlation was also related to 
higher H. pylori infection rates for GC mortality in both 
men and women in Babol, the Caspian Sea coast, 
Iran.[24] A meta-analysis of prospective studies by 
Danesh suggested that GC is 2-3 times more common 
in those infected by H. pylori.[25] 
 
Esophageal cancer 
There is evidence that H. pylori infection has protective 
effect against gastroesophageal cancer. A meta-analysis 
by Islami and Kamangar, using all the searched 
publications from the PubMed and ISI databases, 
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suggested a consistent inverse association between 
esophageal cancer and H. pylori infection.[26] The 
protective effect of H. pylori infection against 
esophageal cancer was further confirmed by the same 
authors in a review paper about H. pylori and its effects 
on human health and disease.[7] 
Gastroesophageal reflux disease (GERD) 
As for esophageal cancer, an inverse association of H. 
pylori with GERD has also been documented. A neuro-
immunological mechanism is responsible for the 
protective effect of H. pylori infection against GERD.[27] 
The role of H. pylori infection in development of GERD 
was investigated in 263 Iranian children. The 
prevalence of H. pylori infection among patients with 
GERD (13/83, 15%) was significantly lower than in 
those without GERD (46/180, 26%) (p < 0.05).[28] 
However, in a case-control study, patients with GERD 
(case group) were compared with normal 
gastrointestinal endoscopic findings (normal group). 
The rate of H. pylori infection was insignificantly lower 
in the case group compared to the control (81.5% vs. 
87.1%, p = 0.29).[29] 
Other gastrointestinal tract diseases 
Recurrent abdominal pain (RAP) is defined as the 
occurrence of at least three episodes of several 
abdominal pain affecting activities over a period longer 
than three months. H. pylori infection, as a possible 
cause of RAP, was investigated in 40 children with 
RAP (mean age = 12.7 ± 1.0 years) and 60 healthy 
children as controls. A similar prevalence of H. pylori 
infection was found in patients with RAP compared to 
the control group (p = 0.112).[30] 
The role of H. pylori infection in upper gastrointestinal 
(UGI) bleeding was investigated in persons with 
hemophilia (PWH). Prevalence of 76.7% and 55% of H. 
pylori infection in patients with and without a history 
of UGI bleeding was considered as an important cause 
of UGI bleeding in PWH (p = 0.03).[31] 
The presence of H. pylori infection in dental plaque 
showed no significant association in patients with and 
without gastric infection (p = 0.6).[32] 
Genotyping and disease association 
The predisposition of H. pylori to cause diseases has 
been attributed to its diverse genome. Several virulent 
genes have been identified to contribute to the 
pathogenicity and severity of these diseases.[33-35] In the 
following section, the most vastly studied virulence 
factors including cag PAI, vacA, babA, the induced by 
contact with epithelium gene A (iceA), the outer 
inflammatory protein A (oipA), the duodenal ulcer 
promoting gene (dupA), and the Helicobacter outer 
membrane gene (hom), in relation to various 
gastroduodenal diseases are discussed. We reviewed 
some aspects of these genotyping including 
frequencies, pathogenicity towards more prevalent 
gastroduodenal manifestations, structural variability, 
and co-existences in details. Table 1 is a summary of 
genotyping distribution pattern of H. pylori in 
association with clinical outcomes in Iranian patients.  
 
Cytotoxin-associated gene pathogenicity-island (cag 
PAI) 
The cag PAI, a well established genotype of H. pylori, is 
a 40-kb region located in the chromosomal glutamate 
racemase gene. Its 35% G+C content distinguishes it 
from the rest of the bacterial genome with a 39% G+C 
content.[34] The cag PAI contains 31 genes of which 6 
encode type IV secretion system mediating bacterial 
factors into the gastric epithelial cells.[36] H. pylori 
strains are classified as type I and II based on whether 
or not they possess the cag PAI. While type II strains 
lack functional cag PAI, type I strains possess the cag 
PAI region and induce more pathogenicity than the 
former strains.[34,37,38] Cytotoxin associated gene A and E 
(cagA and cagE) are two representative genes of the 
cag PAI and are associated with gastritis, PUD and 
gastric adenocarcinoma. The cagA gene is located in 
the right half of the cag PAI and has two ends of a very 
conserved 5´ and a variable 3´. It affects the epithelial 
cells by inducing cellular signaling and elicits a 
number of cellular changes, proliferation, and 
apoptosis.[39] The cagE is located upstream of cagA and 
is involved in the process of interleukin 8 (IL-8) 
expressions.  
 
Simultaneous detection of cagA and cagE were 
assessed in relation to various gastroduodenal 
outcomes. Biopsy specimens were taken and the genes 
were detected using gene specific polymerase chain 
reaction (PCR). Although only cagA-positive strains 
were associated with GC, a higher prevalence of cagE 
strains and identical distribution pattern in PUD and 
GC patients with cagA (Table 1) indicated the potency 
of cagE as a better virulence marker.[40] In another 
study, cagA prevalence (71%) in 128 H. pylori infected 
patients correlated well with PUD in Rasht, north of 
Iran (Table 1).[41] However, no correlations were found 
between cagA genotype and gastritis, PUD, and GC in 
biopsy specimens obtained from 60 male and 40 female 
patients in Isfahan, central Iran (Table 1).[42] 
As discussed previously, the 3´ region of cagA gene in 
H. pylori is highly variable. Depending on the types 
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Table 1. Genotyping distribution pattern of H. pylori isolates in association with clinical outcomes in Iranian patients 
Genotyping 
Hp+ 
isolates 
No. 
NUD
(%) 
PUD*
(%) 
Gastritis
(%) 
GC
(%) 
Overall 
distribution 
n (%) 
City Ref.
cag A+ ** 
cag E+
120 78a
88 
94ab
94 
ND *** 
ND 
100b
100 
101(84) 
109(91) 
Tehran 
Exp. 
40 
(2009) 
cag A+ ** 107 ND 78a 46b ND 
 
76(71) Rasht 
Exp. 
41 
(2009) 
cag A+ 100 ND 72 65 60 68(68) Isfahan 
Exp. 
42 
(2008) 
cag A+ 235 89 96 ND 94 213(91) Tehran 
Exp. 
46 
(2008) 
cag A+
cag E+
cag T+
cag A+/cag E+/cag T+
cag A-/cag E-/cag T-
231 ND 54 
44 
37 
19 
27 
70 
39 
29 
17 
19 
62 
12 
25 
0
25 
154(67) 
90(39) 
70(30) 
40(17) 
47(20) 
Tehran 
Exp. 
49 
(2009) 
cag A+
cag E+
cag T+
80 80 
35 
36 
70 
35 
25 
ND ND 62(77) 
28(35) 
27(34) 
Tehran 
Exp. 
50 
(2008) 
s1 ** 
s2 
m1 ** 
m2 
s1m1 ** 
s1m2 
s2m2 
80 72a
28 
24a
76 
24a
46 
28 
58ab
42 
25 
75 
25ab 
33 
42 
ND 100c
0
61b
39 
61c
39 
0
61(76) 
19(23) 
26(32) 
54(67) 
26(32) 
35(44) 
19(24) 
Tehran 
Exp. 
 
55 
(2010) 
s1 ** 
s2 
m1 
m2 
s1m1 
s1m2 ** 
s2m1 
s2m2 
 
132 68a
31 
33 
55 
28 
28a
4
27 
79b
14 
27 
59 
21 
49b
0
10 
ND ND 93(71) 
36(27) 
42(33) 
74(55) 
35(27) 
43(33) 
4(3) 
31(23) 
Tehran 
Exp. 
 
58 
(2003) 
s1 
s2 
m1 
m2 
s1m1 
s1m2 ** 
s2m1 
s2m2 
 
178 NA**** 
NA 
NA 
NA 
11 
3a
NA 
NA 
NA 
NA 
NA 
NA 
67 
58b
NA 
NA 
NA 
NA 
NA 
NA 
NA 
NA 
NA 
NA 
NA 
NA 
NA 
NA 
NA 
NA 
NA 
NA 
143 (81) 
35 (20) 
129 (73) 
49 (27) 
36(20) 
96(54) 
7(4) 
39(22) 
Shahrekord 
Exp. 
 
57 
(2009) 
cag A+ ** 
s1 
s2 
m1 
m2 
s1m1 
s1m2 
s2m1 
s2m2 
 
137 46 
77 
23 
13 
28 
6
43 
3
2
35a
79 
21 
17 
26 
7
15 
2
2
ND 67b
78 
22 
39 
55 
5
22 
0
0
61(44) 
107(78) 
30 (22) 
25 (18) 
54 (39) 
9 (6) 
39 (28) 
3 (2) 
2 (1) 
Tehran 
Exp. 
 
59 
(2005) 
cag A+
s1 
s2 
m1 ** 
m2 
 
77 ND 79 
81 
NA 
65a
NA 
48 
55 
44 
0b
100 
ND 52(67) 
55(71) 
22(29) 
31(40) 
29(38) 
Rasht 
Exp. 
 
60 
(2009) 
cag A+
s1 
s2 
m1 
m2 
s1m1 
s1m2 
s2m1 
s2m2 
 
96 74 
72 
27 
35 
58 
27 
41 
8
18 
79 
53 
42 
21 
68 
11 
37 
11 
32 
ND 100 
100 
0
0
100 
0
100 
0
0
73(76) 
66(69) 
27(28) 
30(31) 
59(61) 
22(23) 
40(42) 
8(8) 
19(20) 
Tehran 
Exp. 
 
61 
(2008) 
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Genotyping 
Hp+ 
isolates 
No. 
NUD
(%) 
PUD*
(%) 
Gastritis
(%) 
GC
(%) 
Overall 
distribution 
n (%) 
City Ref.
cag A+
s1  
m2  
s1m2 ** 
 
126 NA 
NA 
NA 
33a
NA 
NA 
NA 
NA 
ND NA 
NA 
NA 
54b
93 (74) 
80 (63) 
77 (61) 
47 (37) 
Tehran 
Exp. 
 
63 
(2006) 
cag A+***** 
cag E+
s1 
s2  
m1 
m2 
s1m1 
s1m2 
s2m1 
s2m2 
 
74 72 
52 
67 
33 
26 
74 
21 
46 
5
28 
46 
33 
62 
38 
46 
54 
15 
46 
31 
8
ND 25 
25 
100 
0
25 
75 
25 
75 
0
0
48(65) 
32(47) 
50(68) 
24(32) 
22(30) 
52(70) 
15(20) 
35(47) 
7(9) 
17(23) 
 
Tehran 
Exp. 
 
66 
(2009) 
cag A+ ***** 
s1  
m2 
s1m2   
 
55 74 
NA 
NA 
NA 
62 
NA 
NA 
NA 
ND 
NA 
NA 
NA 
64 
NA 
NA 
NA 
37(67) 
37(67) 
38(69) 
26(47) 
Tehran 
Exp. 
 
67 
(2010) 
cagA+ ***** 
s1m1i1 
s1m1i2  
s1m2i1  
s1m2i2  
s2m2i2  
 
59 76 
NA 
NA 
NA 
NA 
NA 
76 
NA 
NA 
NA 
NA 
NA 
ND 
 
ND 
 
45 (76) 
15 (25) 
1 (2) 
4 (7) 
16 (27) 
16 (27) 
Tehran 
Exp. 
 
68 
(2008) 
cagA+
s1 ** 
s2 
m1 
m2 
i1 ** 
i2 
s1m1i1 
s1m1i2 
s1m2i1 
s1m2i2 
s2m2i2 
 
207 NA 
NAa
NA 
NA 
NA 
44a
NA 
NA 
NA 
NA 
NA 
NA 
NA 
NA 
NA 
NA 
NA 
59ab 
NA 
NA 
NA 
NA 
NA 
NA 
ND 
 
NA 
94b
NA 
NA 
NA 
88c
NA 
NA 
NA 
NA 
NA 
NA 
194(94) 
159(77) 
48(23) 
67(32) 
138(66) 
110(53) 
94(45) 
64(31) 
5(2) 
47(23) 
43(21) 
48(23) 
Tehran 
Exp. 
 
19 
(2009) 
babA2 ** 
 
81 ND 74 68a 80b 58 (72) Isfahan 
Exp. 
72 
(2010) 
babA 
babB 
 
72 48 
77 
33 
92 
ND 75 
94 
NA Tehran 
Exp. 
74 
(2008) 
dupA 157 ND 45 50 46 78 (50) Tehran 
Exp. 
79 
(2008) 
cagA+
homA ** 
homB ** 
138 ND 55 
79a
21a
51 
57b
43b
68 
15c
78c
80 (58) 
75 (54) 
60 (43) 
Sari 
Exp. 
 
83 
(2011) 
Abbreviations: Hp+, H.  pylori positive; ND, not determined; Exp, experimental study; NA, not available 
* PUD was considered as the frequency of genotyping in GU plus DU subjects if data available; otherwise the values are for either GU or DU 
subjects separately.  
** Significant correlation of specific genotype with clinical outcomes (The significant differences are shown with different letters a, b, and c, 
wherever present.) 
*** ND: The specific clinical outcome was not examined in the respective study. 
**** NA: The missing values which were not found or could not be calculated from the respective study. 
***** The values presented in the table are only for Persian subjects examined, as other ethnicities also were compared in the respective 
studies. 
 
and number of repeat regions including R1 (15 bp), R2 
(42 bp) and R3 (147 bp), four types (motifs) of A, B, C, 
and D are contributed to the 3´ end variability of cagA. 
The types are distinguished by the PCR product size 
ranging from 642-651 bp for A type, 756 bp for type B 
and type D, and 813-815 bp for type C.[43] Salehi et al. 
used the CAG1 and CAG2 primers to amplify the 3´ 
region of the cagA gene. They investigated the 
subtypes of 3´ region of cagA gene in H. pylori strains 
and their relation to gastroduodenal diseases.[41] As 
determined by the analysis of the molecular size of the 
PCR products,[43] three subtypes of A, B, and D and no 
C type were detected.[41] A larger number of type C 
phosphorylation motifs has been reported to be more 
pathogenic.[44] Accordingly, the authors indicated no 
association of 3´ region subtypes with clinical 
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outcomes examined.[41] In a similar approach, 3´ end 
variable region of the cagA gene was analyzed and its 
relation with non-ulcer dyspepsia (NUD), PUD, and 
GC was studied.[45] While 94% of the strains were type 
ABC, 3.3% had four copies (ABCC type), and 3.3% had 
two copies (AB type). Further analysis of deduced 
protein sequences confirmed that there was no 
detection of type D sequences in the studied 
population. Moreover, no relation with any of the 
diseases was found.[45] 
In another study, the frequency of cagA in H. pylori 
strains was assessed by means of genotyping and 
serological assessment of host antibodies.[46] Single 
biopsy sampling resulted in 90.6% of cagA-positive 
strains with no correlation to clinical outcomes (Table 
1). Multiple biopsy sampling in this study resulted in 
78.4% of strains harboring cagA gene. The cagA+/cagA-
strains contributed to 16.5% of the results. Still, this 
result confirmed the more suitability of multiple 
biopsy sampling compared to single sampling in 
predicting the genotyping frequencies as indicated by 
others.[47] Furthermore, the presence of anti-CagA 
antibodies showed an association with clinical 
manifestations when categorized in three groups of 
NUD, PUD, and GC. PUD and GC occurrence were 
strongly associated with the presence of anti-CagA 
antibodies and no anti-CagA sero-negative cases were 
found in patients with these two diseases. Considering 
the similar frequency of anti-CagA antibodies and 
cagA genotyping (90.7% and 90.6%, respectively) and 
their association with clinical outcomes, serum 
reflection of cagA genotypes was found to be a suitable 
approach in predicting disease outcome in patients at 
high risk.[46] 
While cagA and cagE are located more downstream of 
the cag I region in the cag PAI, the cagT gene is located 
in the upstream cag II region and reported to be related 
to severe clinical outcomes.[48] Pathogenicity of the cag 
PAI was determined by analysis of the latter three 
genes by Baghaei et al.[49] Neither single genes nor 
combination of cag I and cag II regions (cagA, cagE, 
and cagT) were found to be correlated with 
gastroduodenal diseases (Table 1). Although there was 
no relation between cagA status and disease in this 
study, higher prevalence of cagA gene in different 
clinical isolates was thought to be a better marker than 
cagE for determining disease association (Table 1).[49] In 
a similar study, a lower prevalence of cagT and a 
higher frequency of cagA in PUD patients again 
indicated the importance of cagA as a virulence 
marker. They concluded that the presence of both cag I 
and cag II regions of the cag PAI was not necessary for 
developing ulcer disease.[50] 
Vacuolating cytotoxin gene A (vacA) and its co-
existence with cagA genotype 
The vacA, one of the vastly studied virulence 
determinants of H. pylori, has a mosaic structure 
comprising three families of allelic variation including 
the signal sequence region (s1, s2), the mid region (m1, 
m2), and the recently discovered intermediate region 
(i1, i2), located between the signal and middle regions 
of the vacA genotype.[51] Inducing cytoplasmic 
vacuolation in epithelial cells,[52] inducing apoptosis 
through cytochrome release from mitochondria,[53] 
suppression of epithelial proliferation and migration, 
and inducing cytoskeletal changes[54] are attributed to 
the cytotoxin activity of the vacA gene (protein).[51,55] 
Applying PCR-based methodology, different 
combinations of allelic variations such as s1m1, s1m2, 
and s2m2 were detected from dyspeptic patients who 
underwent upper gastrointestinal endoscopy. 
Cytotoxic activity of vacA gene seemed to be attributed 
to these different combinations. The vacA genotyping 
revealed a strong association between the s1 and s1m1 
genotypes and GC when compared to NUD and PUD 
in Iranian patients (Table 1).[55] This association was 
further confirmed assessing the vacuolating activity of 
different genotypes using cultured HeLa cell 
monolayers. Interestingly, s1m1 type protein was 
capable of producing prominent cell vacuolation, 
whereas s2m2 lacked the ability.[55] The vacA s1 and 
s1m1 genotypes were also the dominant genotypes 
among Iranian patients with high rate (90%) of H. 
pylori infection in another study.[56] However, the 
collective assessment of the vacA genotype signal 
sequence and middle region determined a majority of 
s1m2 genotype in patients with PUD which was 
significantly correlated with the disease (p < 0.05) in 
two other studies (Table 1).[57,58] 
The first study to demonstrate the frequency of cagA 
and vacA genotypes was performed in 2005 in Iran by 
Siavoshi et al. who obtained gastric biopsy specimens 
from 137 patients to examine the association between 
mixed strain genotyping and clinical outcomes. Cancer 
occurred more frequently in patients infected with 
cagA+. In addition, vacA s1 was the most common 
genotype in patients with PUD (Table 1). However, 
due to a very small sample size of cancer patients 
(18/137) and the fact that there was no significant 
association between cagA+ or vacA s1 genotypes with 
PUD, cagA and vacA genotypes were not considered 
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as helpful in predicting disease outcome in this 
study.[59] Similarly, the co-existence of vacA subtypes 
and cagA were studied in relation to clinical outcomes 
from biopsy samples taken from patients in Rasht, 
north of Iran. The genotype s1m1/cagA+ was the most 
frequent genotype among patients with PUD. In 
gastritis patients, most of the strains were s2m2/cagA-
genotype. The vacA s1 and m1 were found as 
predominant in patients with PUD, whereas all 
patients with gastritis had m2 allele (Table 1).[60] 
In another study by Jafari et al., irrespective to clinical 
outcomes (NUD, PUD, and GC), vacA s1m2/cagA+
genotype was predominant in strains isolated from 
Tehran, Iran.[61] As with vacA genotypes, the 
prevalence of the cagA gene was not correlated with 
any clinical outcomes. The presence of cagA was 
significantly associated with the vacA s1 genotype (p < 
0.001). They also found an 8% prevalence for s2m1 
genotype which has been reported to be rare in Iranian 
populations.[55] Yet, vacA s1m2 and cagA+ strains 
correlated well with gastroduodenal diseases in other 
studies.[62,63] 
The geographical variation in H. pylori genotypes and 
its link to the severity of gastroduodenal disease were 
previously reported.[64,65] In Iran, in addition to Persian 
and Azeri Turks as the major ethnic groups, four other 
distinct ethnic groups including Kurds, Lurs, Arabs, 
and Afghans, predominate. Distribution of H. pylori 
cagA, cagE, and vacA subtypes were determined by 
PCR to compare different ethnic groups living for a 
long time in Tehran, Iran.[66] The cagA was found in 
65%, 73%, and 71% of isolates from Persians, Turks, 
and other ethnicities (as one group), respectively. No 
correlation was found between cagA status and clinical 
manifestations including NUD, PUD, and GC in any 
ethnic group (p = 0.13, p = 0.76, and p = 1.0, 
respectively). The cagE status was the highest among 
other ethnicities (Kurds, Lurs, Arabs, and Afghans) 
compared to Persians and Turks (77%, 47%, and 30%, 
respectively; p = 0.008). The predominant vacA 
genotypes were s1 and m1 in all three ethnic groups 
(Persians, Turks, and other ethnicities). As for cagA, no 
correlation with clinical outcomes was found for cagE 
and vacA genotypes.[66] Consistently, no significant 
associations were found between cagA, cagE, and vacA 
genotypes and clinical outcomes (NUD, PUD, and GC) 
comparing Iranian and Afghanian isolates of H. pylori 
in another study.[67] In addition, the co-existence of 
triple positive genotype of cagA+/cagE+/vacA s1 
indicated no association with NUD and PUD in any of 
two ethnicities.[67]
H. pylori infection is an important risk factor for GC, 
the second most important cause of cancer deaths 
worldwide.[25] A higher incidence of GC in Iran was 
hypothesized to be due to the differences in virulence 
markers between H. pylori strains from Iran and those 
from Iraq.[68] In fact, a similar frequency of cagA 
genotype was seen in both isolates from Iran and Iraq 
(77% and 71%, respectively) with association to PUD (p 
< 0.01) only in strains from Iraq. Although no 
significant association between vacA alleles and PUD 
existed among Iranian strains, vacA i1 was associated 
with PUD in strains from Iraq (p < 0.02). Moreover, 
cagA presented more motifs (ABCC) in Iranian strains 
compared to Iraqi strains (ABC). The cagA gene with 
more phosphorylation motifs could be contributed to 
the higher incidence of GC in Iran. Nonetheless, other 
host and environmental factors were considered to be 
more important in GC pathogenesis in the two 
countries.[68] 
Rhead et al. identified the third polymorphic 
determinant of vacuolating activity, i-region, by 
nucleotide sequencing and allele specific PCR. Using a 
simple PCR-based typing system, the association of i-
region with GC was examined in 73 Iranian patients 
who underwent endoscopy. Strains with s1m1 subtype 
were predominantly i1 and s2m2 strains were all i2. 
However, the i-region varied in s1m2 subtypes. 
Moreover, vacuolating activity varied between the 
strains depending on various subtypes. While all 
strains with s1m1i1 genotype showed vacuolating 
activity and strains with s2m2i2 were nonvacuolating, 
strains with s1m2 genotype varied and only the s1m2 
strains possessing i1 showed the vacuolating activity. 
GC was associated with vacA s1 allele (p < 0.05), cagA 
(p < 0.005), and m1 allele (p < 0.05) compared to the 
NUD group as control. Interestingly, vacA i-type strain 
was also significantly correlated with GC (p < 0.005). 
Previous studies indicated the s1m1 and s1m2 
genotypes of vacA as suitable virulence markers. Yet, 
due to the fact that i-type included all pathogenic 
strains with s1m1 and those of s1m2 with vacuolating 
activity, i-type was considered as a sufficient marker 
for disease pathogenesis.[51] 
Similar to many previous studies, Douraghi et al. 
assessed clustering of active virulent genes in 
association with NUD, PUD, and GC in 207 H. pylori 
infected patients. They also studied vacA 
polymorphism in correlation with histopathological 
findings. Strains with s1 and s1m1i1 were related to 
GC (p < 0.005 and p = 0.001, respectively), whereas 
s2m2i2 genotype was correlated with NUD. 
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Multivariate logistic regression analysis found i-region 
superior to s and m regions of the vacA gene. 
Possession of s1i1/cagA+ genotype was an independent 
predictor of metaplasia (OR = 3), dysplasia (OR = 9.9) 
and risk of GC (OR = 6.9).[19] However, vacA alleles and 
cagA revealed no association with the types of gastritis 
with or without atrophy or IM in the first-degree 
relatives of GC patients.[18] 
H. pylori has long been a strict human stomach 
pathogen. Yet, the reservoir of this pathogen and its 
mode of transmission are unclear. A study on dental 
plaque of 100 patients with dyspepsia was performed 
in Tehran, Iran. H. pylori infection was found in 40% of 
samples of which 62.5% were cagA-positive. 
Accordingly, dental plaque was estimated to be a 
suitable reservoir and a possible route of transmission 
for H. pylori.[69] In another study, vacA genotypes 
isolated from stomach and saliva were compared in 
250 patients undergoing upper gastrointestinal tract 
endoscopy in Shahrekord, Iran and 189 (75.6%) were 
found to be H. pylori positive. The vacA analysis was 
performed for 36 patients whose saliva and gastric 
samples were both positive for H. pylori. A high 
homology (61%) was obtained in vacA genotypes 
between stomach and saliva. Still, the diversity of 
38.3% in H. pylori strains between two sites and a high 
rate of H. pylori infection (75.6%), firstly suggested 
more than one strain to possibly exist in stomach and 
saliva of the same patient, and secondly estimated 
saliva as a suitable reservoir for H. pylori infection.[70]
babA 
The gene product is a member of family of H. pylori 
outer membrane proteins. It mediates the adherence of 
H. pylori to the Lewis blood group antigens on human 
gastric epithelial cells.[71]   Three bab alleles have been 
identified as babA1, babA2, and babB. The first two 
ones are identical except that babA1 has a 10-bp 
deletion of the translational initiation codon. Therefore, 
only babA2 product is necessary for binding activity.[71] 
Relation of babA2 genotype with chronic gastritis, 
PUD, and non-cardia gastric cancer was examined in 
Isfahan, Iran.[72] The frequency of babA2 was 58 (71.6%) 
in 81 H. pylori positive specimens. There was no 
correlation between genotype and clinical outcomes 
when gastritis and PUD were compared (p = 0.673), but 
a significant correlation was observed comparing 
gastritis and non-cardia gastric cancer (p < 0.001) 
(Table 1).[72] This association was further confirmed in 
another study in which a 40.6% frequency of babA2 
genotype was significantly associated with GC 
compared to NUD and PUD patients (p = 0.0004).[73] 
Relationship between babA and babB genotypes and 
disease outcome in another study showed a higher 
frequency of babA limited to GC patients, whereas 
babB was higher among GC and PUD subjects (Table 
1).[74] 
iceA 
The iceA is a signaling gene, induced by contact with 
epithelium. There are two allelic types of the gene: 
iceA1 and iceA2. The products of two allelic variants 
are different and the expression of iceA1 is up-
regulated following contact between H. pylori and 
human epithelial cells.[8] The prevalence of iceA 
genotypes in 75 H. pylori strains isolated from PUD 
patients was investigated in Sari, north of Iran. The 
iceA1 and iceA2 genotypes verification was 
determined via PCR. The iceA1 genotype (64%) was 
more prevalent than iceA2 (21.3%). A significant 
correlation between iceA1 genotypes and PUD 
occurrence (p = 0.03) indicated that iceA1 gene can be 
used as a reliable marker in predicting the clinical 
outcomes of H. pylori infection.[75] In another study, 
iceA genotypes were determined in 30 H. pylori 
positive isolates using PCR. Both alleles, iceA1 and 
iceA2, were found in 66.7% and 23.8% of the isolates, 
respectively. The presence of two strains (9.5%) with 
no iceA1 and iceA2 genotypes seemed to show the 
presence of a new allele other than iceA1 and iceA2 
alleles in H. pylori.[76] 
oipA 
The oipA is an important virulence factor associated 
with enhanced IL-8 secretion and increased 
inflammation in vitro as well as clinical outcomes.[77] It 
encodes one of the outer membrane proteins and is an 
inflammation-related gene located approximately 100 
kb from the cag PAI on the H. pylori chromosome.77 A
study of various H. pylori virulence factors compared 
this gene in different major ethnic groups in Tehran, 
Iran.[66] The prevalence of oipA was found to be 51%, 
33%, and 71% in Persians, Turks, and other ethnicities 
(Kurds, Lurs, Arabs, and Afghans), respectively. No 
correlation with clinical outcomes was found for any 
ethnicity. In Persians, it was more common in NUD 
(63%) than in PUD (15%) or GC patients (0%) (p = 
0.001).[66] 
 
dupA 
The dupA is a recently described virulence factor, 
comprising the jhp0917 and jhp0918 genes which form 
one continuous gene. Lu et al. noticed a significant role 
of dupA in development of duodenal ulcer (DU) which 
was related to neutrophil infiltration and a high level 
of IL-8 production by epithelial cells. On the other 
hand, possession of this gene appeared to be protective 
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against gastric adenocarcinoma.[78] The presence of the 
jhp0917 and jhp0918 genes was assessed in 157 H. 
pylori infected patients with DU, gastric ulcer (GU), 
gastritis, and GC using gene specific PCR. After the 
tests, 78 (49.7%) strains were positive for both, the 
jhp0917 and jhp0918, genes. Possession of dupA was 
not a promoting or protective determinant for any of 
clinical outcomes. However, the presence of dupA 
gene was inversely associated with dysplasia (p < 0.05) 
as the final stage towards GC and 83.3% of dysplasia-
positive strains were colonized with dupA-negative 
strains. Moreover, dupA indicated inverse association 
with lymphoid follicles as a consequence or relatively 
long-term infection by H. pylori.[79] 
hom 
The gene products constitute a small paralogous 
family of proteins that contain alternating hydrophobic 
motifs and signal sequences in the C terminus which 
are typical of other outer membrane proteins.[80] The 
homA and homB are the most studied members of the 
hom family and are 90% identical. These genes vary in 
the central domain where six different allelic variants 
within a 300-bp region exist. It has been suggested that 
the number of homB genes affects the number of 
bacteria adhering to host cells and that the presence of 
homB is associated with secretion of the pro-
inflammatory cytokine IL-8, PUD, and GC.[81,82] The 
prevalence of virulence genes homA, homB, and cagA 
in a population at very high risk of cancer was assessed 
in the north of Iran (Table 1). The cagA genotype had 
no significant impact on disease state (p = 0.2654). The 
homA and homB genotypes indicated significant 
association with disease status in any comparison 
stratification (Table 1). The co-existence of cagA and 
homA was inversely associated (r = -0.279; p = 0.001), 
whereas a significant positive association was found 
between cagA and homB (r = 0.243; p = 0.004). In this 
population, the high prevalence of homB among GC 
patients (78%) indicated that homB may be a better 
predictor of more virulent strains of H. pylori and 
influence the severity of disease manifestation.[83] 
DISCUSSION 
 
In total, including six duplicates, 398 studies have been 
reported in various research areas relating to H. pylori 
infection in Iran since 1995. One can query these 
studies in the web of Knowledge database using the 
terms "Helicobacter pylori" as title and "Iran" as address 
in the time-span of 1995-2011. As for other 
countries,[64,65] we found the importance of knowledge 
on the geographical variation in H. pylori genotypes 
and its link to the severity of gastroduodenal disorders 
reported in Iran to figure out the further investigations. 
We focused on the virulence factors of H. pylori and 
their associations with disease status as many studies 
have demonstrated the importance of H. pylori 
virulence factors in disease progression.  
 
The cagA, as a marker for the presence of the cluster of 
genes (cag PAI), is one of the best studied virulence 
markers of H. pylori. The frequency of cagA-positive 
isolates has been reported to be nearly 100% in some 
countries in East Asia such as Japan, China, and Korea, 
60-80% in some other countries such as Taiwan, 
Turkey, Malaysia, India, and Bangladesh, and 25-60% 
in Bahrain, Israel, and Jordan.[46] The cagA genotype 
varied geographically ranging from 44% to 94% in 
Iranian populations. A strong correlation between 
possessing cag PAI and its representative gene cagA 
and severe clinical outcomes has been reported in 
several studies.[37,38] We found a significant association 
of cagA genotype with chronic gastritis,[70] PUD,[50,84] 
and GC.[40,59,63] However, the majority of studies 
indicated no influence of cagA genotype on the 
progression of diseases.[18,42,46,49,61,62,66-68,83] Accordingly, 
in other Asian countries where the majority of H. pylori 
infected individuals harbor the cagA genotype, the 
association between this genotype and disease state 
was not observed.[85,86] The high prevalence of cagA 
genotype in Iran as well as East Asian countries on one 
hand,[46] and the number of studies illustrating no 
influence of this genotype on disease status on the 
other hand, questions the value of cagA genotype as a 
suitable marker when predicting the related clinical 
outcomes in this part of the world.[46] In Iran however, 
the majority of studies investigating the relation of 
cagA genotype with disease status have been 
performed in Tehran, the capital city, probably due to 
the more facilities and equipped laboratories (Table 1). 
Therefore, further investigations are needed in other 
areas to elucidate whether the cagA genotype could be 
a reliable marker for disease progression. 
 
Another vastly studied virulence factor of H. pylori is 
the vacA gene. The variations in the three regions of 
vacA gene of H. pylori s, m, and i region are known to 
cause the differences in vacuolating activity. In a meta-
analysis comparison, the prevalence of vacA alleles in 
single and in combinations varied significantly among 
different countries in the Middle East.[87] Countries in 
the northern parts such as Turkey and Iraq had a 
higher frequency of s1 allele (79.4%) compared to 
Jordan, Saudi Arabia, Kuwait, and Israel as southern 
countries (44.5%, p < 0.001).[87] Consistent with other 
countries in the northern part of the Middle East we 
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found a frequency of 72% for vacA s1 in our analysis. 
The vacA s1 was the most common genotype in 
Iranian populations followed by m2 and m1 alleles 
(55.3% and 36.1%, respectively). Comparing vacA 
genotypes in the Middle East, our findings were in a 
great consistence in particular for vacA m1 allele for 
which the frequency was estimated as 36.1% in 
neighbor countries such as Turkey and Iraq. However, 
vacA m1 genotype showed a much lower frequency in 
southern countries of the Middle East especially in 
Israel with a prevalence of only 8%. In the Middle East, 
the combination of vacA s and m genotypes indicated 
s1m2 as the predominant genotype (42.1%), followed 
by s1m1 (30.5%) and s2m2 (26.1%). The average 
frequency of vacA s2m1 was only 1.4% in the Middle 
East. Our findings indicated vacA s1m2 as the most 
common subtype of combined genotypes (40.7%), 
followed by s1m1 and s2m2 (21.3% and 18.8%, 
respectively) which is again in agreement with other 
regions in the Middle East.  
 
Overall, unlike the cagA status, the majority of studies 
emphasized the implication of vacA polymorphic 
structure in increasing risk of gastroduodenal diseases. 
However, no association of vacA genotypes and 
disease status was found in some other studies.[18,61,67] 
Looking at the association between vacA genotypes 
and disease status, a significant association was 
observed between s1 genotype and gastritis,[62,70] 
PUD,[56-58,60,88] and GC.[19,51,55] The vacA m1 genotype 
indicated strong correlation with PUD[60] and GC,[55] 
whereas m2 genotype correlated with gastritis.[60] The 
vacA s1m1 genotype was correlated with GC,[55] 
whereas s1m2 allele indicated significant correlation 
with gastritis,[62,63,70] PUD,[57,58] and GC.[63] In our search, 
there were only two studies reporting the third region 
of vacA genotype, i subtype. Compared to the s and m 
regions, it was suggested that i region of the vacA 
genotype is a superior marker in predicting the results 
concerning the disease status.[19,51] Mixed polymorphic 
determinant of vacA genotype s1m1i1 indicated a 
significant prevalence in subjects with GC and IM, 
while s2m2i2 genotyping was most prevalent in NUD 
patients.[19] Co-existence of cagA and vacA genotypes, 
s1m1/cagA+, s1m2/cagA+, s1i1/cagA+, and s1/cagA+
were all correlated with disease status in some 
studies.[60-63] A strong correlation of vacA genotype 
with clinical outcomes in the majority of the studies 
implies that vacA in any polymorphic structure could 
still be considered as the best virulence marker when 
predicting disease outcomes. 
 
Despite the vast investigation on cagA and vacA 
genotypes, there are considerably rare studies on the 
association of other H. pylori virulence factors and 
clinical outcomes in Iran. We found reports on the 
association of the adherence factor of babA2 and 
disease status, particularly GC.[72,73] The frequencies of 
babA2 allele varied from 40.6% (Sari, northern Iran) to 
71.6% (Isfahan, central Iran) in these studies.[72,73] 
Another adherence factor, iceA, with two allelic types 
of iceA1 and iceA2, was studied in two cities of Babol 
and Sari, north of Iran.[75,76] A higher frequency was 
noticed for iceA1 genotype compared to iceA2 allele. 
Moreover, a significant two-tailed frequency correlated 
iceA1 with PUD compared to iceA2 allele in the study 
by Talebi et al.[75] There was no correlation for an 
inflammation-related gene oipA and disease status in 
different ethnicities living for a long time in Iran.[66] The 
frequency of 49.7% of dupA indicated no effect 
towards any of clinical outcomes, whereas it was 
inversely associated with precancerous lesions.[79] It 
was indicated that homB may be a better predictor of 
more virulent strains of H. pylori than homA, even 
though they were both correlated with the severity of 
disease manifestation. Although different markers of 
H. pylori were emphasized as useful when predicting 
disease outcomes in some studies, the inconsistent 
researches and the scarcity of data made any 
conclusion or even comparison impossible. Further 
studies are necessary to estimate the actual effect of 
these genotypes in Iranian populations. It is also 
important to determine whether other pathogenic 
factors such as H. pylori neutrophil-activating protein 
(Hp-NAP),[86] H. pylori arginase (rocF),[87] and H. pylori 
adhesion protein A (HpaA)[88] other than previously 
studied virulent factors could be useful in predicting 
the disease outcomes.  
 
The discrepancy observed in the frequency of H. pylori 
genotypes and their association with disease state in 
Asian countries as well as developed countries[89] could 
not be explained precisely. Yet, several causes may 
contribute to the observed discrepancy: i) subject 
selection and the fact that in most of the studies 
subjects were recruited among patients referring to the 
health centers with symptomatic clinical outcomes and 
could not be then representative of general population; 
ii) lack of enough sample size with respect to clinical 
symptoms and genotyping; iii) the geographic origin of 
the patients (host) and bacterial and environmental 
factors; IV) the various detection methods of H. pylori 
in the first step and subsequent analysis of genotyping 
using PCR-based technology applying various primers 
and laboratory protocols; and V) type (single vs. 
multiple) and site of sampling which varied from 
cardia, corpus, and pylorus to the antrum in different 
studies. 
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Further suggestions 
Overall, according to the search performed, the 
number of studies increased from 2 to 74 yearly, over 
the period (1995-2011). We observed a gap of 
information and a less tendency towards some aspects 
of H. pylori investigation before 2004. While there was 
no drastic change in any of the categories, there was 
more frequency towards all six categories after the year 
2004. Interest to investigate the association of H. pylori 
with various diseases was increased over the period 
and became the main contributing factor in 2011. 
Treatment strategies were investigated during the 
whole period except in 1996 for which no study was 
found in any category. Antimicrobial resistance was 
rarely studied before 2004. Further on, it fluctuated 
over the time and gradually increased in the recent 
years. Antimicrobial resistance is important if it leads 
to a successful treatment of H. pylori infection.[90] A
great geographical variation has been reported for 
bacterial resistance of H. pylori strains against various 
antimicrobials.[91,92] The co-investigation strategies 
would therefore be required to make us aware of the 
local antibacterial resistance rate and the subsequent 
appropriate regimen to eradicate H. pylori infection.  
 
We found few papers over the period of our search 
estimating the actual prevalence of H. pylori infection 
among general population. Population-based studies 
were also found in other databases investigating the 
seroprevalence of H. pylori infection in a few 
geographical areas. Selecting sample size 
representative enough to general population, further 
research on the prevalence of H. pylori infection in 
different geographical areas would be another matter 
of interest. Considering a very high rate of H. pylori 
infection reported in a number of studies, effective 
public health interventions in some areas is necessary. 
Eventually, comprehensive research strategies for H. 
pylori infection from the very first step of childhood 
monitoring and diagnosis towards treatment strategies 
and the subsequent eradication evaluation for different 
geographical areas are suggested. 
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